MEXIDOL: instructions for use
Clinico-pharmacological group: Antioxidant product
Release form, composition and packaging:
Tablets, film-coated 1 tab.
etilmetilgidroksipiridina succinate 125 mg
Excipients: lactose monohydrate - 97.5 mg povidone 25 mg, magnesium stearate - 2.5 mg.
The composition of the film shell: Opadry II white 33G28435 - 7.5 mg (hypromellose 3 mg, titanium dioxide - 1.875 mg, lactose monohydrate - 1.575 mg, polyethylene glycol (macrogol) - 0.6 mg, triacetin - 0.45 mg).
— the consequences of acute stroke, including after transient ischemic attacks in phase subcompensation (as a prophylactic courses);
— mild traumatic brain injury, consequences of craniocerebral injuries;
— encephalopathy of different Genesis (dyscirculatory, dysmetabolic, posttraumatic, mixed);
syndrome vegetative dystonia;
— mild cognitive disorder atherosclerotic Genesis;
— anxiety disorders with neurotic and neurosis-like States;
— Coronary artery disease (in the complex therapy);
— relief of withdrawal syndrome in alcoholism with the prevalence of neurosis and vegetative-vascular disorders, post-abstinent disorders;
— conditions after acute intoxication antipsychotic means;
— asthenic conditions, and also to prevent the development of somatic diseases under the influence of extreme factors and loads;
— exposure to extreme (stress) factors.
— acute liver failure;
— acute renal failure;
— hypersensitivity to the drug.
In connection with insufficient knowledge of drug action:
the children's age;
— lactation (breast-feeding).
Dosage: Inside of 125-250 mg 3 times/day; maximum daily dose — 800 mg (6 tab.). The duration of treatment is 2-6 weeks; for the relief of alcoholic abstinence for 5-7 days. Treatment out gradually, reducing the dose for 2-3 days.
The initial dose of 125-250 mg (1-2 tab.) 1-2 times/day with a gradual increase to produce a therapeutic effect; the maximum daily dose — 800 mg (6 tab.).
Duration of therapy in CHD patients is at least 1.5-2 months. Repeated courses (the physician) is preferably carried out in the spring and autumn periods.
Overdose: In case of overdose may develop drowsiness.
Drug interactions: In a joint application Mexidol increases the effects of benzodiazepines, antidepressants, anxiolytics, antiparkinsonian and anticonvulsant agents. Mexidol reduces the toxic effect of ethanol.
Pregnancy and lactation:Mexidol is contraindicated during pregnancy and lactation (breastfeeding) due to insufficient knowledge of drug action.
Side effects: From the digestive system: may cause an individual adverse reactions dyspepsia or dyspeptic character.
Other: allergic reactions are possible.
Terms and conditions storage: The drug should be stored out of reach of children, dry, protected from light place at temperature not exceeding 25°C. shelf Life - 3 years. Do not use after date shown on packaging.
Special instructions: Mexidol can be combined with all drugs used for the treatment of somatic diseases.
Use in Pediatrics: Mexidol is not prescribed to children due to insufficient knowledge of drug action.
Effects on ability to drive vehicles and management mechanisms: During the period of treatment must be careful when driving and occupation of other potentially hazardous activities, require high concentration and psychomotor speed reactions.
If impaired renal function: The drug is contraindicated in acute renal failure.
When disorders of liver function: The drug is contraindicated in acute liver failure.